JP2008528480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528480A5 JP2008528480A5 JP2007551814A JP2007551814A JP2008528480A5 JP 2008528480 A5 JP2008528480 A5 JP 2008528480A5 JP 2007551814 A JP2007551814 A JP 2007551814A JP 2007551814 A JP2007551814 A JP 2007551814A JP 2008528480 A5 JP2008528480 A5 JP 2008528480A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- peptide
- composition according
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 125000000539 amino acid group Chemical group 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 20
- 230000004927 fusion Effects 0.000 claims 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- 230000000903 blocking effect Effects 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- 229930182817 methionine Natural products 0.000 claims 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- 230000006044 T cell activation Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 150000008574 D-amino acids Chemical class 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 150000008575 L-amino acids Chemical class 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- -1 AAi Substances 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000019399 Colonic disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000021510 thyroid gland disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64560505P | 2005-01-24 | 2005-01-24 | |
| PCT/IL2006/000096 WO2006077601A2 (en) | 2005-01-24 | 2006-01-24 | HIV-1 gp41 FUSION PEPTIDES FOR IMMUNOMODULATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528480A JP2008528480A (ja) | 2008-07-31 |
| JP2008528480A5 true JP2008528480A5 (enExample) | 2009-03-05 |
Family
ID=36692632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551814A Abandoned JP2008528480A (ja) | 2005-01-24 | 2006-01-24 | 免疫調節用ＨＩＶ−１ｇｐ４１融合ペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090270312A1 (enExample) |
| EP (1) | EP1843777A2 (enExample) |
| JP (1) | JP2008528480A (enExample) |
| CN (1) | CN101115498A (enExample) |
| AU (1) | AU2006207181A1 (enExample) |
| CA (1) | CA2595414A1 (enExample) |
| WO (1) | WO2006077601A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10138276B2 (en) | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| US8986712B2 (en) | 2009-11-29 | 2015-03-24 | Yeda Research And Development Co., Ltd. | Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation |
| CN103732238A (zh) * | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| EP2866820A1 (en) * | 2012-06-27 | 2015-05-06 | Yeda Research and Development Co. Ltd. | Peptides derived from hiv gp41 for treating t-cell mediated pathologies |
| KR20170080579A (ko) | 2014-10-01 | 2017-07-10 | 플랜트 헬스 케어, 인코포레이티드 | 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도 |
| US10856546B2 (en) | 2014-10-01 | 2020-12-08 | Plant Health Care, Inc. | Hypersensitive response elicitor peptides and use thereof |
| BR112018069945A2 (pt) | 2016-04-06 | 2019-02-05 | Plant Health Care Inc | micróbios benéficos para distribuição de peptídeos ou proteínas efetoras e uso dos mesmos |
| MX389549B (es) | 2016-04-06 | 2025-03-20 | Plant Health Care Inc | Peptidos derivados de inductores de respuesta de hipersensibilidad y su uso. |
| WO2018037416A1 (en) * | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
| WO2018067582A2 (en) * | 2016-10-03 | 2018-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide immunogens and their use |
| KR20200049594A (ko) * | 2018-10-24 | 2020-05-08 | 주식회사 툴젠 | 조작된 면역 세포 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5230887A (en) * | 1990-07-11 | 1993-07-27 | Immune Network Research Ltd. | Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction |
| US5444044A (en) * | 1992-03-26 | 1995-08-22 | New York Blood Center | Synthetic polypeptides as inhibitors of HIV-1 |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| ATE294859T1 (de) * | 1999-09-17 | 2005-05-15 | Univ Keio | Polypeptid, humanin, welches das absterben von nervenzellen hemmt |
| DE19957838C2 (de) * | 1999-11-25 | 2002-11-21 | Pette Heinrich Inst | Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden |
| WO2004103312A2 (en) * | 2003-05-19 | 2004-12-02 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
-
2006
- 2006-01-24 CA CA002595414A patent/CA2595414A1/en not_active Abandoned
- 2006-01-24 EP EP06701338A patent/EP1843777A2/en not_active Withdrawn
- 2006-01-24 AU AU2006207181A patent/AU2006207181A1/en not_active Abandoned
- 2006-01-24 US US11/722,064 patent/US20090270312A1/en not_active Abandoned
- 2006-01-24 CN CNA2006800022095A patent/CN101115498A/zh active Pending
- 2006-01-24 JP JP2007551814A patent/JP2008528480A/ja not_active Abandoned
- 2006-01-24 WO PCT/IL2006/000096 patent/WO2006077601A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7170081B2 (ja) | 新規なポリペプチド | |
| US10745442B2 (en) | Compstatin analogs with improved pharmacokinetic properties | |
| RS66991B1 (sr) | Peptidni inhibitori interleukin-23 receptora i njihova primena u lečenju inflamatornih bolesti | |
| CA3104418A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| JP2023511551A (ja) | インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 | |
| CA3049889A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| CN114341161A (zh) | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 | |
| JP2008528480A5 (enExample) | ||
| WO2021146458A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| SG178721A1 (en) | Amino acid prodrugs | |
| EP3074032A1 (en) | Fatty acid derivatives of dimeric inhibitors of psd-95 | |
| CA3210657A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| WO2019080919A1 (zh) | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 | |
| US10632187B2 (en) | Hemagglutinin-binding peptide | |
| AU2023320411A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| WO2022223007A1 (zh) | 抗病毒多肽化合物 | |
| JP2005510469A5 (enExample) | ||
| JPWO2008050830A1 (ja) | 抗ｈｉｖ剤 | |
| WO2025137159A1 (en) | Human interleukin (il)-17 cytokine binding peptides | |
| WO2025043696A1 (zh) | 抗病毒多肽类似物 | |
| WO2012139519A1 (zh) | 环肽及其医药用途 | |
| HK1227702A1 (en) | Novel polypeptides |